Nervous system disorders Uncommon: Headache Not known: Convulsions*, Dizziness Heart disease Not known: Palpitations Vascular pathologies Uncommon: Hypertension, Hypotension Respiratory, thoracic and mediastinal pathologies Not known: Dyspnea Gastrointestinal disorders Common: Vomiting, Nausea, Diarrhea, Abdominal pain Uncommon: Dysgeusia, Dyspepsia, Dry mouth Skin and subcutaneous tissue disorders Uncommon: Abnormal skin odor ** Not known: Itching, Skin rash Musculoskeletal and connective tissue disorders Uncommon: Muscle spasms Not known: Myasthenia***, Muscle tension Systemic disorders and conditions related to the administration site Uncommon: Chest pain, Feeling abnormal, Pyrexia, Injection site reaction**** Diagnostic tests Uncommon: Increased blood pressure Very rare: Increased INR*****
"Eli Lilly says next-generation weight loss drug clears crucial obesity trial." CNBC
The brand names OpenLoop Healthcare Partners as one Clinical Partner among "other independent entities," and lists four named pharmacies
10.1111/jdi.12063 27 HuY.PengX.DuG.ZhangZ.ZhaiY.XiongX.et al (2022)
Tolerance to Melanotan-2 cycling develops when melanocortin receptors (MC1R for pigmentation, MC4R for appetite suppression) downregulate after 23 weeks of continuous daily dosing
